VRTX · 8-K · 20260803PR000256
Product Launch and Transition
VERTEX PHARMACEUTICALS INC / MA · 2026-08-03 · Importance 83 · Surprise 82 · From source text
ALYFTREK revenue reached $573.6 million in the second quarter of 2026, compared with $156.8 million a year earlier, while TRIKAFTA/KAFTRIO revenue was $2.50 billion versus $2.55 billion. Continued ALYFTREK uptake, including new patient initiations, is driving the transition within Vertex’s CF portfolio. Vertex secured reimbursement for ALYFTREK in four additional countries, bringing the total to 25 reimbursed countries. The company also signed a letter of intent with the Pan-Canadian Pharmaceutical Alliance for reimbursement in eligible Canadian patients aged six and older.
Key facts
- ALYFTREK revenues for the three months ended June 30, 2026 were $573.6 million compared to $156.8 million in the prior year period. source
- Vertex has submitted global regulatory submissions for ALYFTREK in children 2 to 5 years of age following Phase 3 data showing 65% of children reached carrier sweat chloride levels of < 30 mmol/L and a mean reduction in sweat chloride of 9.6 mmol/L from a baseline on TRIKAFTA. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +12.5% | ALYFTREK revenues for the three months ended June 30, 2026 were $573.6 million compared to $156.8 million in the prior year period. |
| revenue | positive | probable | — | Vertex has submitted global regulatory submissions for ALYFTREK in children 2 to 5 years of age following Phase 3 data showing 65% of… |